What are Affimers?

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Affimers stem from the drive to generate alternative methods of studying protein binding and function, which can complement information provided by antibodies. As a type of affinity reagent, affimers are biophysically stable scaffolds of proteins that can be reused. Affimers can be made from two scaffolds: Adhiron scaffolds and human stefin A scaffolds. The stefin A scaffold is engineered from human stefin A protein, whereas Adhiron is synthetic. The Adhiron synthetic protein was originally made from the sequence of cystatin, and is very thermally stable. The Adhiron and stefin A scaffolds are structurally related. To select an appropriate affimer, screening is done to find suitable reagents for the target protein. The chosen coding regions are then cloned into an expression vector in Escherichia coli, and the recombinant protein was purified over the course of a week. This allows for generation of high quality proteins for diverse applications.

What are the Applications of Affimers?

Affimers can be combined with traditional biological tests to increase our understanding of proteins. For example, affimers have been used in affinity assays, among others. They have also been used in biosensors and in cell cultures to manipulate cell signaling. Affimers have been successfully applied both in vitro and in vivo. Some of the applications that have been tested using affimers include cell imaging, super resolution microscopy, protein function modulation, magnetic nanoparticle formation, and MRI reagent development. Affimers with enhanced specificity for tubulin have been used in super resolution microscopy with high success, and can target regions of the tubulin structure that antibodies are typically restricted from. It is likely that more applications will be discovered in the future as the use of affimers becomes more widespread. For example, thanks to growing libraries of affimers, it has been possible to create affinity microarrays to discover biomarkers and potential pharmaceuticals. By finding biomarkers, affimers have been applied to cancer studies, where they have been used to target a protein in tumor vessel formation called the VEGF receptor.

What are the Advantages of Affimers?

Affimers are small in size, stable at different temperature ranges, relatively easy to generate, and offer appealing opportunities to complement the shortcomings of antibodies. Their small size is thought to be one of the attributes making affimers more sensitive than antibodies when used in histochemical staining, as they can penetrate tissues better. Affimers are both commercially available and can be synthesized by individual laboratories using publicly available methods, thereby ensuring it is accessible to the entire scientific community. One key advantage of affimers, as opposed to antibodies or nanobodies, is the speed at which they can be screened and developed. The screening process for affimers involves three iterations of phage display and ELISA assays. This can be carried out in 12 days, which is significantly less than the time needed for antibody and nanobody animal inoculation times. Furthermore, the screening process by which binding reagents are identified is more efficient because the target proteins are screened in a folded state.

Shortcomings and Future Development

Affimers are typically most successfully isolated when antigens of high quality are used. These are presented via biotin or streptavidin on plates and beads. However, isolation of certain recombinant proteins can be more challenging. For example, SH2 proteins expressed in mammalian cells are challenging to extract.

The success of suitable affimer selection using commercial antigens appears to depend on the source, as only certain brands seem to be viable for affimers.

Sources

Tiede C, et al. (2017). Affimer proteins are versatile and renewable affinity reagents. eLife. https://doi.org/10.7554/eLife.24903
Roberts J.P. (2013). Biomarkers Take Center Stage. www.genengnews.com/.../
Bedford R, et al. (2017). Alternative reagents to antibodies in imaging applications. Biophyiscal Reviews. https://doi.org/10.1007/s12551-017-0278-2

Last Updated: Apr 8, 2023

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What’s your vision for BenevolentBio?

I want us to disrupt the drug discovery and development process and to look at each place on the drug discovery and development pipeline, so that we can be much better at getting the right target, much quicker at getting the right compound and much more confident that those compounds have the right characteristics which mean they will be safe and well tolerated. Then we can go to the right patient population with the right dose, so we would have a much leaner, more successful process and be able to demonstrate the value of our AI technology.

Source: www.news-medical.net ↗

02You are a regular at Pittcon. What does the event offer to researchers around the world?

Pittcon offers ease of networking, with a very large number of scientists in many different fields, all together in one location. It is easier to hear a wider variety of talks than at any other meeting I have been to, so the number of people you can access and talk to is much easier at Pittcon than virtually any meeting worldwide.

Source: www.news-medical.net ↗

03Your early research focused on predicting molecular properties such as solubility using machine learning. What did that teach you about data-driven property prediction?

Data-driven models, such as Quantitative Structure Activity Relationships (QSAR), are incredibly attractive because they offer rapid methods for predicting molecular properties, including those that are difficult to access through fundamental chemical and physical theory. For new molecules, in related regions of chemical space to the training data, they can often be very accurate. The challenge is that they typically do not generalize across large diverse chemical and biological spaces. Therefore real care is needed when applying them to novel chemistry or biology. Some attempts to build more widely applicable QSAR models have been made in recent years, but most models in use today are still built for specific chemistries and properties owing to the scale and complexity of chemical space. When I started this work, especially for solubility predictions, the datasets were modest by today’s standards, often hundreds to a few thousand molecules. One of the first things that teaches you is to explore the data carefully, assess its quality and quantity, and only then move forward with modeling. The aim is to capture genuine relationships between numerical molecular descriptions and important target endpoints, but those relationships may be only locally generalizable. I also think the phrase “simple descriptors” is interesting. Some are simple, such as atom counts or bond counts, but others rely on detailed parameterization, group contributions, and graph-theoretical techniques. We still see these descriptors used today, sometimes alongside embeddings from graph neural networks or language models. The main lesson for me is that there is no single workflow. Each dataset, model, and end-use case needs careful thought.

Source: www.news-medical.net ↗

04What was done in this study?

In the study, published in Scientific Reports, the researchers built on their earlier discovery of the peptide called AC253. This compound was tested in mice with AD. It was found to block the attachment of beta-amyloid to a brain cell receptor called the amylin receptor, and thus inhibit its toxic effects, as shown by an improvement in spatial memory. However, it is difficult to administer this compound because it doesn’t cross the blood-brain barrier in large amounts, and is quickly broken down in the blood. The dosage must therefore be massively increased, pushing up the amounts required for efficacy and increasing the difficulty of administration, besides enhancing the chances of an immune reaction. One way out is to convert the formulation into a pill rather than an injectable form. The complex structure of AC253 makes this difficult as well. Instead, the team devised an ingenious solution. They cleaved the compound into smaller amylin peptides, or chains of 12-14 amino acids, and tested each for its anti-amyloid activity in old mice which showed signs of AD. In this way, they found two short peptides that had the same effects as the larger compound. In particular, the researchers identified a segment that was common to both peptides, namely, SQELHRLQTY.

Source: www.news-medical.net ↗

05What do these findings mean for the future of COTI-2?

These finding support proceeding to clinical trials with COTI-2 in patients with cancers having p53 mutations. Dr. Mills has established that COTI-2 is potentially effective in a wide range of p53 mutation types.

Source: www.news-medical.net ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

What are Affimers?

Skip to:

How are Affimers Made?

What are the Applications of Affimers?

What are the Advantages of Affimers?

Shortcomings and Future Development

Sources

Helpful context for this guide

Related questions

Peptide Therapy Guide Editorial Team

Skip to:

How are Affimers Made?

What are the Applications of Affimers?

What are the Advantages of Affimers?

Shortcomings and Future Development

Sources

Related questions

Peptide Therapy Guide Editorial Team

BIOVECTRA and Revolution Biomanufacturing partner to deliver integrated mRNA Design and GMP production services

Research suggests new therapeutic targets for broad-spectrum antiviral drugs

Active Alpha-Synuclein Proteins in Research

Transgenic carrots producing nisin protein show promise as natural food preservatives